Wen Shirui, Huang Kailing, Zhu Haoyue, Li Peihong, Zhou Luo, Feng Li
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Front Neurol. 2022 Mar 14;13:838222. doi: 10.3389/fneur.2022.838222. eCollection 2022.
Corona Virus Disease 2019 (COVID-19), the novel coronavirus disease, is now a global pandemic. Vaccination can significantly reduce the mortality rate caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). There are currently several effective vaccines that have been introduced. Inactivated COVID-19 vaccine is one of these options and is generally considered safe. Neurofascin (NF) plays an important role in keeping the functionality of the node of Ranvier. We report here a rare case of anti-NF186+ chronic inflammatory demyelinating polyneuropathy (CIDP) in a 23-year-old male patient who was vaccinated with inactivated COVID-19 vaccine prior to the onset. This report adds a new possible rare side effect of a COVID-19 vaccine and provides a case for the clinical effectiveness of rituximab (RTX) in patients with anti-NF186+ CIDP.
2019冠状病毒病（COVID-19），即新型冠状病毒病，现已成为全球大流行疾病。接种疫苗可显著降低由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的死亡率。目前已有几种有效的疫苗投入使用。灭活COVID-19疫苗是其中一种选择，通常被认为是安全的。神经束蛋白（NF）在维持郎飞结的功能方面发挥着重要作用。我们在此报告一例罕见病例，一名23岁男性患者在接种灭活COVID-19疫苗后发病，出现抗NF186 +慢性炎症性脱髓鞘性多发性神经病（CIDP）。本报告增加了COVID-19疫苗一种新的可能的罕见副作用，并提供了利妥昔单抗（RTX）治疗抗NF186 + CIDP患者临床有效性的病例。
